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Background/Aims: In the 2-acetylaminofluorene (2-AAF)/ 
70% partial hepatectomy (PHx) model, the mechanism 
underlying the differentiation of activated hepatic oval cells 
(HOCs) into hepatocytes and bile ductile cells is unclear. We 
investigated the role of cyclooxygenase-2 (COX-2) in HOCs 
and the relationship between COX-2 and extracellular matrix 
proteins in cellular proliferation. Methods: Reverse transcrip-
tion-polymerase chain reaction, immunohistochemical stain-
ing, and Western blotting were used to assess COX-2 expres-
sion. The co-localization of COX-2 with Thy1, c-Met, epithelial 
cell adhesion molecule, and α-smooth muscle actin was also 
examined. Additionally, we investigated whether connective 
tissue growth factor (CTGF), fibronectin (FN), extracellular 
signal-regulated kinase 1/2 (P-ERK1/2), and AKT were 
expressed in HOCs. Results: The expression of COX-2, pros-
taglandin E2 receptors, and c-Met was upregulated in HOCs. 
However, HOCs treated with the COX-2 inhibitor NS398 
showed decreased COX-2, CTGF, FN, and AKT expression, 
whereas P-ERK1/2 was unaffected. Additionally, NS398 
inhibited HOC proliferation, but not the proliferation of HOCs 
cultured on FN-coated dishes. Furthermore, the prolifera-
tive response of HOCs treated with NS398 was reversed by 
hepatic growth factor treatment. Conclusions: These results 
suggest that HOC proliferation is mediated through COX-2, 
extracellular FN expression, and AKT activation. Thus, COX-
2 plays an important role in HOC proliferation following acute 
injury. (Gut Liver 2011;5:367-376)
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INTRODUCTION
The proliferative liver responds to traumatic, chemical, meta-
bolic, infectious, and other injuries by activating a complex 
mixture of cytokines and chemokines from remnant tissue.
1 In 
hepatic injury animal models, the administration of 2-acety-
laminofluorene (2-AAF) before and during hepatic injury is 
associated with increased numbers of hepatic oval cells (HOCs) 
and increased differentiation to hepatocytes and bile ductu-
lar cells during liver regeneration, as the impaired hepatocyte 
response-to-growth signal suppresses hepatocyte proliferation.
2-5 
HOCs display distinct phenotypic markers, including CD34, c-
kit, c-Met, alpha-fetoprotein (AFP), and Thy1 surface antigen.
6-8 
Among them, Thy1, which is expressed on bone marrow cells 
and stem cells in the fetal liver, plays an important role in he-
matopoiesis and hepatic development.
9-11 In an animal model of 
HOC activation, Thy1
+ HOCs express high levels of connective 
tissue growth factor (CTGF), which is critical for HOC activa-
tion during liver regeneration.
12 HOCs that possess epithelial cell 
adhesion molecule (EpCAM) (EpCAM
+ HOCs) are potential adult 
hepatic epithelial progenitors, but they do not express the previ-
ously reported hematopoietic stem cell markers CD34, c-kit, or 
Thy1.
13 
The conversion of arachidonic acid to prostaglandins (PGs), 
which is the irreversible step in prostanoid biosynthesis, is 
mediated by two cyclooxygenases (COXs), COX-1 and COX-2, 
which are encoded by unique genes located on different chro-
mosomes.
14,15 Between them, COX-2, which was initially identi-
fied as an immediate early growth-response gene, is induced 
by a wide variety of stimuli such as cytokines, hormones, mito-368  Gut and Liver, Vol. 5, No. 3, September 2011
gens, and growth factors,
16-20 and is frequently overexpressed in 
various tumor cells.
21 The effects of COX-2 and PG-dependent 
signaling on HOC activation have been reported in liver cancer. 
The COX-2 inhibitor-induced reduction in HOC number may be 
due to the COX-2-dependent inhibition of Akt phosphorylation 
and the induction of apoptosis.
22 
During liver remodeling, including hepatic fibrosis and liver 
regeneration, several growth factors affect HOC proliferation 
and differentiation.
1,23 Among them, hepatocyte growth factor 
(HGF) has a variety of activities in various cells, exerting mito-
genic
24 and morpho-organogenic
25 effects by activating c-Met, 
a tyrosine kinase receptor.
26 When HGF binds the c-Met recep-
tor, signaling molecules such as extracellular signal-regulated 
kinase (ERK)
27 and AKT protein kinase
28 are activated. Among 
them, the phosphoinositide 3-kinase (PI3K)/AKT signaling path-
way is dedicated to a variety of system-related biological effects 
of HGF, including protection against apoptosis in primary hepa-
tocytes.
29 
Hepatic stellate cells (HSCs) influence the growth and de-
velopment of HOCs. HSCs in the periportal regions increase in 
response to liver injury
30 and produce fibronectin (FN), a com-
ponent of the extracellular matrix (ECM), which is crucial for 
liver regeneration. CTGF on an FN-concentrated provisional 
matrix facilitates HOC activation, and FN is critical for HOC 
proliferative functions.
31 A positive correlation has been report-
ed between FN concentration and COX-2 expression in human 
cancer cells.
32-34 However, the precise mechanism linking FN 
and COX-2 expression during liver regeneration is unclear. 
Herein, we explored COX-2 expression during HOC acti-
vation and liver regeneration following 2-AAF/70% partial 
hepatectomy (PHx), and the nature of the signals that modulate 
COX-2 expression. The co-localization of c-Met and EpCAM 
with COX-2 clearly demonstrated that COX-2 is expressed in 
HOCs. Our results show that an increasing level of COX-2 and 
c-Met expression in HOCs may occur through PG signaling 
during liver regeneration in the 2-AAF/PHx model. Moreover, 
FN was expressed in HOCs. The relationships between COX-2 
and proliferation-related signals during liver regeneration were 
also investigated. The COX-2 inhibitor NS398 decreased HOC 
proliferation and significantly suppressed CTGF, FN, and AKT 
signaling, but did not affect phosphorylated ERK 1/2 (P-ERK 
1/2). Interestingly, NS398 did not impair HOC proliferation in 
FN-coated dishes, indicating that FN induces HOC proliferation 
through COX-2 signaling. COX-2 expression increased when 
HOCs were challenged with a COX-2 inhibitor, followed by a 
change to an HGF-containing medium.
MATERIALS AND METHODS
1. Animals and experimental groups
Male Fischer rats weighing 120 to 150 g were divided into 
3 equal groups (20 rats each). All animal experiments were 
conducted according to protocols approved by the Animal 
Care and Use Committee of the Catholic University of Korea. 
Time-released 2-AAF (35 mg/pellet over 14 days) treatment 
was achieved using a product supplied by Innovative Research 
(Sarasota, FL, USA). The pellets were inserted subcutaneously 7 
days before PHx. Three rats from each group were killed, and 
their livers were collected. All time points are indicated as days 
after PHx treatment.
2. HOC culture
A Thy1-specific antibody in conjunction with magnetic-
activated cell sorting (MACS) was used to isolate HOCs, with 
yields averaging 3×10
6 cells per animal on day 9. Thy1
+ cells 
were isolated by MACS, as described previously.
5 HOCs were 
cultured in Iscove’s MDM solution containing 10% fetal bovine 
serum (FBS), 5 μg/mL insulin, 100 U/mL penicillin, and 100 mg/
mL streptomycin (Life Technologies, Grand Island, NY, USA).
3. Reverse transcription-polymerase chain reaction (RT-
PCR) analysis of COX-2 and prostaglandin E2 receptor 
mRNA expression
RT-PCR analysis was conducted on total RNA isolated from 
tissues from normal, PHx and 2-AAF/PHx livers, as well as iso-
lated HOCs, using an RNeasy Kit (Qiagen, Valencia, CA, USA). 
Two micrograms of RNA were used for each round of cDNA 
synthesis. RT was performed using a GeneAmp RNA PCR Kit 
and a DNA thermal cycler (Perkin Elmer, Norwalk, CT, USA), 
which were also used for PCR. The primers used for COX-
2, EP1, EP2, EP3, and EP4 were: 5′-AAG CCT CGG CCA GAT 
GCC AT-3′ forward and 5’-GTA GTA CTG TGG GAT TGA TAT 
C-3′ reverse (COX-2, 340 bp), 5′-ACG TGG GTC ACT ACG AGC 
TAC-3’ forward and 5’-GCT GTG GTT GAA GTG ATG GAT C-3′ 
reverse (EP1, 301 bp), 5′-GGG TCT CCT TGC TCT TCT GTT-3′ 
forward and 5′-CTT TCG GGA AGA GGT TTC ATC C-3′ reverse 
(EP2, 392 bp), 5′-GTA TGC CAG CCA CAT GAA GAC-3′ forward 
and 5′-GAT GTG CCC CAT AAG CTG GAT AGC-3′ reverse (EP3, 
370 bp), and 5′-GCC AAG TGT GGT GAA AGA CAT-3′ forward 
and 5′-CTC TCT GGC TCC CAC TAA CCT -3′ reverse (EP4, 482 
bp). Briefly, mRNA was reverse-transcribed and the cDNA was 
subjected to 30 cycles of denaturation at 95
oC for 1 minute, an-
nealing at 55
oC for 1 minute, and an extension period of 72
oC 
for 1 minute. The amplified products were subjected to 1% aga-
rose gel electrophoresis and stained with ethidium bromide. The 
mRNA levels were normalized using GAPDH as a housekeeping 
gene.
4. Immunohistochemical staining
Double-immunofluorescence staining for Thy1.1 (BD Biosci-
ences, San Jose, CA, USA), c-Met (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), and EpCAM (Abcam, Cambridge, MA, 
USA) with COX-2 (Transduction Lab, Franklin Lakes, NJ, USA) 
was performed to verify the identity of the HOCs. Addition-Bae SH, et al: Hepatic Oval Cell Proliferation via COX-2 Signaling  369
ally, immunofluorescence staining of α-smooth muscle actin 
(SMA) (Abcam) with COX-2 was performed, using a previously 
described cytochemical method, to exclude myofibroblasts as 
the COX-2 source.
35 Immunostaining for OV-6 (R & D Systems, 
Minneapolis, MN, USA), COX-2, Thy1.1, albumin (DakoCytoma-
tion, Carpinteria, CA, USA), AFP (DakoCytomation), FN, and 
CD45 (BD Biosciences) was performed on isolated Thy1
+ HOCs. 
Signals were detected using a Vector ABC Kit (Vector Laborato-
ries, Burlingame, CA, USA) and 3,3’-diaminobenzidine tetrahy-
drochloride (DakoCytomation). Finally, BrdU (DakoCytomation) 
staining was conducted for the HOC proliferation assay on FN-
coated culture dishes following NS398 treatment, as described 
Fig. 1. Proliferation of hepatic oval cells (HOCs) on day 9 after induction of the 2-acetylaminofluorene (2-AAF)/70% partial hepatectomy (PHx) 
model. Immunohistochemical (IHC) staining is conducted to detect OV-6, thymus cell antigen1 (Thy1), and cyclooxygenase (COX)-2. (A) Hema-
toxylin and eosin staining (magnification, ×400). (B) OV-6 IHC staining in activated HOCs. OV-6 is a hepatic oval cell marker (magnification, 
×400). (C, E) Thy1 and (D, F) COX-2 IHC staining in activated HOCs (magnification, ×100 and ×400, respectively).370  Gut and Liver, Vol. 5, No. 3, September 2011
previously.
36 Cells (4.5×10
4) in 6-well culture dishes were inocu-
lated on FN-coated or uncoated dishes with 10% FBS supple-
mented with Iscove’s MDM for 24 hours, after which a medium 
containing 100 μM NS398 was used in some cases. After 1 hour 
of incubation, 100 μM BrdU cell-labeling reagent was added. 
The cells were fixed after 24 hours, and the percentage of BrdU-
labeled nuclei was determined by counting >100 nuclei in three 
random fields (×400 magnification).
5. Western blot analysis
Enhanced chemiluminescence Western blotting detection re-
agents were purchased from Amersham Life Science (Arlington 
Heights, IL, USA), and a monoclonal mouse anti-COX-2 anti-
body was purchased from PharMingen (San Diego, CA, USA). 
Polyclonal rabbit anti-c-Met, -CTGF, -FN, -AKT, -p-AKT, -ERK 
1/2, -p-ERK 1/2, and -β-actin antibodies were purchased from 
Santa Cruz Biotechnology. All other chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).
6. Regulation of COX-2 expression by NS398 and HGF
HOCs were selected to evaluate the inhibitory growth effect of 
the COX-2 inhibitor NS398 (Cayman Chemicals, Ann Arbor, MI, 
USA). COX-2 expression was inhibited in HOC cultures treated 
with 100 μM NS398, as described previously.
37 Cells (3×10
5) 
were grown in Iscove’s MDM supplemented with 10% FBS, 100 
μg/mL penicillin, 20 μM HGF, and 0.25 μg/mL streptomycin 
and then stimulated with 20 μM HGF for various time periods.
7. Statistical analysis 
All experiments were repeated a minimum of three times. All 
RT-PCR, BrdU staining, and Western blot data are expressed as 
the mean±SD. The data in some figures are from a representa-
tive experiment, which was qualitatively similar to replicate 
experiments. Statistical significance was determined by compar-
ing the two groups using a two-tailed Student’s t-test. Asterisks 
in the figures indicate significant differences (p≤0.05) between 
experimental groups and the corresponding control.
RESULTS
1. COX-2 gene and protein expression in activated HOCs 
HOCs appeared as dark blue areas in hematoxylin and 
eosin-stained liver sections, due to their large nuclei and small 
amount of cytoplasm, with numerous HOCs in the periportal 
region on day 9 after 2-AAF/PHx treatment (Fig. 1A). HOCs 
were confirmed by labeling with OV-6 (Fig. 1B). An additional 
immunomarker widely utilized in HOC labeling, Thy1.1, was 
also used (Fig. 1C and E). These results confirm that the 2-AAF/
PHx model can be used effectively to activate HOCs in peri-
portal regions during liver regeneration, consistent with previ-
ous observations.
38 Additionally, COX-2-expressing cells were 
evident around the periportal region (Fig. 1D and F), and COX-
2 staining in the HOCs was detected in the cytoplasm (Fig. 1F, 
2D, 2G, 2J, and 2M). Double-immunofluorescence staining was 
performed on serial liver sections to verify COX-2 expression in 
the HOCs and to assess whether the HOCs co-expressed Thy1, 
c-Met, EpCAM, and α-SMA with COX-2 (Fig. 2). Fig. 2F and I 
show that in some HOCs COX-2 (Fig. 2D and G) was colocal-
ized with the HOC markers Thy1 (Fig. 2E) and c-Met (Fig. 2H), 
whereas the co-localization of COX-2 (Fig. 2J) and EpCAM (Fig. 
2K) did not occur in the peri-bile ductile or hepatic lobule area 
(Fig. 2L). Moreover, the co-localization of COX-2 (Fig. 2M) with 
the myofibroblast marker α-SMA (Fig. 2N) was not observed (Fig. 
2O). These results indicate that Thy1
+ HOCs expressed COX-2 
and c-Met but not EpCAM or α-SMA. 
The next experiment assessed COX-2 expression in total 
RNA extracted from normal liver, 2AAF/PHx-treated liver (on 
day 9), and PHx-treated liver (after 12 hours), and sorted Thy1
+ 
HOCs by RT-PCR (Fig. 3A). COX-2 expression was not detected 
in normal liver, but was detected in the activated HOC model 
(2AAF/PHx), the liver regeneration model (PHx), and the sorted 
Thy1
+ HOCs, suggesting that COX-2 participates in HOC activa-
tion during liver regeneration. Furthermore, COX-2 and c-Met 
(HGF receptor) expression was examined in the activated HOC 
model by Western blotting. Normal liver did not induce COX-2 
expression, but HOC induction resulted in a progressive increase 
in COX-2 expression on days 3-13 after 2-AAF/PHx (Fig. 3B). 
The detection of COX-2 on day 3 after 2-AAF/PHx suggests 
that the COX-2-induced PG pathway plays a role in HOC acti-
vation. Our immunofluorescence staining results revealed that 
the HOCs expressed COX-2 and the HOC markers (albumin and 
AFP), but that they did not express CD45. Interestingly, FN was 
also evident in the HOCs, indicating that it might play a role in 
HOC activation or proliferation in the 2AAF/PHx liver model 
(Fig. 3C).
2. Detection of PG receptors in HOCs
The finding that COX-2 was expressed in HOCs indicated that 
a COX-2-mediated PG pathway might be involved in the HOC 
proliferation mediated by PG receptors. Indeed, PGE2 binds 
its receptors, designated EP1, EP2, EP3, and EP4, which have 
been implicated in carcinoma cell proliferation.
39,40 RT-PCR was 
performed for each EP receptor subtype to determine their ex-
pression profiles in HOCs (Fig. 4). Tissues from normal rat liver 
and rat liver after PHx, as well as sorted Thy1
+ HOCs expressed 
all four PG receptors (though faint EP3 expression was noted in 
the Thy1
+ HOCs), indicating the existence of these receptors in 
Thy1
+ HOCs and their possible role in proliferation.
3. Role of COX-2 and ECM in activated HOCs
To explore the downstream events in the PG pathway, HOCs 
were cultured with 100 μM NS398, which suppressed HOC 
proliferation. CTGF is a downstream mediator of the fibrogenic 
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stimulates the expression of ECM genes in many biological pro-
cesses. Western blotting of HOCs cultured with NS398 showed 
increased levels of the ECM proteins CTGF, FN, and COX-2 (Fig. 
5). Moreover, AKT phosphorylation was inhibited by COX-2 sig-
naling, whereas ERK 1/2 phosphorylation was not. These results 
are consistent with the expression of CTGF, FN, and phospho-
serine-specific AKT in activated HOCs via the PG pathway, and 
they indicate that ERK functions independently of PG signaling. 
FN is an ECM molecule that induces cell proliferation by induc-
ing COX-2 signaling and subsequent PGE2 production.
33 Fur-
thermore, we examined the HOC proliferation rate in FN-coated 
cultured dishes using BrdU staining. When HOCs were cultured 
on non-FN-coated dishes as a control and FN-coated dishes in 
the absence of NS398, dramatic proliferation was evident in 
the FN-coated dishes (Fig. 6A). However, the proliferation on 
non-FN-coated dishes was suppressed significantly when HOCs 
were treated with NS398. Interestingly, HOC proliferation was 
not inhibited significantly on FN-coated dishes, despite NS398 
treatment (Fig. 6B). These observations are evidence of a posi-
tive interaction between HOCs and FN, which is critical for HOC 
proliferation.
COX-2 expression increased in a time-dependent manner fol-
lowing a change to HGF-containing medium after NS398 expo-
sure for 24 hours (Fig. 7), suggesting a role for HGF in increased 
COX-2 expression during HOC proliferation.
DISCUSSION
We demonstrated that COX-2 is expressed and that ECM pro-
teins were produced in activated HOCs through COX-2-induced 
Fig. 2. Co-localization of cyclooxy-
genase (COX)-2 with thymus cell 
antigen1 (Thy1), c-Met, epithelial 
cell adhesion molecule (EpCAM), 
and α-smooth muscle actin markers. 
Double-immunofluorescence label-
ing with COX-2 (red; left panels in 
A, D, G, J, and M) and Thy1, c-Met, 
EpCAM, and α-smooth muscle actin, 
respectively (middle panels in B, E, 
H, K, and N). Yellow staining on the 
merged pictures indicates co-local-
ization of the two proteins in hepatic 
oval cells (HOCs). Co-localization of 
COX-2 (A, D, G, J, and M) and Thy1 
(B and E; merged images, C and F), 
c-Met (H; merged image, I), EpCAM 
(K; merged image, L), and α-smooth 
muscle actin (N; merged image, O) 
showing colocalization. 4’,6-Diamid-
ino-2-phenylindole counterstaining, 
blue (Original magnification: A-C, 
×100; D-O, ×400).372  Gut and Liver, Vol. 5, No. 3, September 2011
PG signaling during liver regeneration. The relationship between 
COX-2 and HOC proliferation-related signals involved two ECM 
proteins (CTGF and FN) and AKT activity. The COX-2 inhibitor 
NS398 decreased HOC proliferation and significantly suppressed 
CTGF and FN expression and AKT activation, but not ERK 1/2 
activation. Moreover, the observation that NS398 did not affect 
HOC proliferation on FN-coated dishes indicates that the FN-
induced proliferation of HOCs occurs through COX-2-induced 
PG signaling. The observation that HOCs treated with NS398 
were shifted to an HGF-containing medium for HOC regulation 
is entirely consistent with a role for HGF in HOC proliferation.
In the liver regeneration model, HOCs participate in liver 
regeneration by activating a complex mixture of compounds, 
including cytokines and growth factors.
2-6 Several growth fac-
tors (e.g., HGF and epidermal growth factor) and intracellular 
signaling pathways (e.g., ERK and Akt) are important regulators 
of HOC-mediated liver regeneration.
41-43 Furthermore, the upreg-
Fig. 3. Analysis of cyclooxygenase (COX)-2 expression in the 2-acetylaminofluorene (2-AAF)/70% partial hepatectomy (PHx) model and in sorted 
hepatic oval cells (HOCs). (A) RT-PCR analysis of COX-2 in normal liver (NL), 2AAF/PHx liver (day 9), PHx liver (after 12 hours), and Thy1
+-sorted 
HOCs. (B) Western blot of a whole-liver homogenate demonstrating the accumulation of c-Met and COX-2. β-actin is used as a loading control. (C) 
Immunofluorescence staining (Texas Red) to examine the expression of COX-2, albumin, alpha-fetoprotein (AFP), fibronectin (FN), and CD45 in 
Thy1
+ HOCs sorted from the livers of 2AAF/PHx-treated rats on day 9 (original magnification, ×600)
Fig. 4. Detection of prostaglandin (PG) receptors in hepatic oval cells 
(HOCs). RT-PCR amplification of the PG receptor family (EP1-4) in 
normal liver (NL), the liver regeneration model (PHx), and Thy1
+-
sorted HOCs. GAPDH is used as an internal standard.
Fig. 5. Western blot analysis of NS398-treated hepatic oval cells 
(HOCs). HOCs cultured with 100 μM NS398 for 24 hours are exam-
ined. Control cells are treated with DMSO without NS398. NS398 
suppress cyclooxygenase (COX)-2, connective tissue growth factor 
(CTGF), fibronectin (FN), and AKT expression, but not ERK expres-
sion. β-Actin is used as a loading control.Bae SH, et al: Hepatic Oval Cell Proliferation via COX-2 Signaling  373
ulation of ECM proteins is important for HOC proliferation dur-
ing liver regeneration induced by 2-AAF/PHx.
12,31 However, the 
underlying mechanism linking the COX-2-induced PG signaling 
pathway with HOC-mediated liver regeneration is unclear.
We determined that COX-2 expression occurred in the HOC 
activation model, in which 2AAF pellets were implanted into 
animals to inhibit hepatocyte proliferation. Normal liver tissue 
did not express COX-2, and COX-2 and EP1-4 were expressed 
and upregulated in liver tissue obtained from the 2AAF/PHx 
model and from isolated HOCs. 
EpCAM is a cell surface marker for HOCs.
44 Immunofluores-
cence microscopy showed that COX-2-expressing cells were 
stained with the HOC markers albumin (albeit weakly), AFP, FN, 
and c-Met, but not with EpCAM or α-SMA. Therefore, the sort-
ed Thy1
+ cells were HOCs, contrary to the opinion that EpCAM
+ 
cells are representative of the HOC population.
An increase in c-Met and COX-2 expression was observed 
over the course of regeneration, suggesting that the PG signal-
ing pathway plays a role in HOC activation and proliferation. 
Previous studies reported that selective COX-2 inhibitors re-
duced cancer growth in carcinogen-treated rodents, inhibited 
various cancer cell lines,
45,46 and delayed wound healing by re-
ducing inflammation-induced epithelial cell proliferation.
47 We 
found that NS398 suppressed HOC proliferation and decreased 
CTGF, FN, and AKT expression during liver regeneration. In 
contrast, the proliferation of HOCs cultured on FN-coated dishes 
was not inhibited by COX-2 inhibitor treatment. These results 
indicate that COX-2 and ECM proteins might be involved in 
HOC activation through PG-dependent and -independent sig-
naling pathways.
The physical condition of the normal subendothelial ECM is 
essential for maintaining different functions in all liver cells. 
We found that NS398 decreased COX-2, CTGF, FN, and AKT 
expression, but not ERK expression, and that it suppressed HOC 
proliferation. However, NS398-mediated inhibition was obvi-
ated by the presence of FN on the culture dishes. These results 
suggest that COX-2 is critical for HOC proliferation during liver 
regeneration, and that the interaction between ECM proteins 
and COX-2 is essential for liver regeneration after liver injury.
HGF is a multifunctional cytokine with mitogenic, morpho-
genic, and tumor-suppressing activities, which are present on 
the majority of epithelial cells, including HOCs.
48,49 Despite this 
Fig. 6. Analysis of the proliferation of hepatic oval cell (HOC) grown on fibronectin (FN)-coated culture dishes by BrdU staining. (A) BrdU-labeled 
nuclei in HOCs. Control, non-FN-coated dish in the absence of NS398; FN, FN-coated dish in the absence of NS398; NS398, non-FN coated dish 
with NS398; FN/NS398, FN-coated dish with NS398 (*p<0.05) (original magnification, ×200). (B) Quantification of proliferating HOCs by BrdU 
staining.
Fig. 7. Hepatic growth factor (HGF) induces cyclooxygenase (COX)-
2 expression in hepatic oval cells (HOCs) treated with NS398. HOCs 
were cultured in 100 μM NS398 for 24 hours and transferred to 
medium containing 5 ng/mL HGF. A representative Western blot is 
shown. The time-dependent increase in COX-2 expression following 
HGF exposure is apparent.374  Gut and Liver, Vol. 5, No. 3, September 2011
broad spectrum of biological activities, HGF is most likely the 
physiological hepatotrophic factor that triggers or modulates 
liver regeneration. HGF induces HOC proliferation in a 2-AAF/
PHx rat model,
50 and PGs induce HGF expression in skin fibro-
blasts. In contrast, the inhibition of PG synthesis by dexametha-
sone reduces HGF production in these cells.
51 In the present 
study, c-Met and COX-2 protein levels increased during liver 
regeneration in the rat 2-AAF/PHx model, and COX-2 expres-
sion decreased gradually following NS398 treatment in a time-
dependent manner, suggesting that the effects of NS398 on 
HOC proliferation are mediated by a COX-2-dependent signal-
ing pathway (data not shown). Our findings are consistent with 
those of a previous report, although a reduction in the number 
of oval cells is associated with a reduced incidence of liver 
cancer in mice.
22 In the context of human chronic liver disease, 
these results are of considerable relevance, as liver regeneration 
is paralleled by changes in the number of hepatic progenitor 
cells, which can differentiate into hepatocytes and bile ductular 
cells.
COX-2 expression in HOCs was upregulated following ex-
posure to an HGF-containing medium after NS398 treatment. 
These results suggest that HGF has a proliferative effect on 
HOCs, and that COX-2 mediates the effects of HGF on HOC 
proliferation due to binding of the growth factor to the c-Met 
receptor on the HOC surface. Thus, COX-2 may be used with 
ECM and HGF to investigate the regulation of HOC proliferation 
during liver regeneration. 
There are some limitations to this study. First, the identifica-
tion of the PGE2 receptors was preliminary; additional function-
al assays are needed. Second, a clear organized analysis of the 
signal transduction mechanisms involved in HOC proliferation, 
including total and phosphorylated ERK and AKT, is required.
In conclusion, we showed that COX-2 is expressed in acti-
vated HOCs, which proliferate through COX-2, extracellular FN, 
and AKT signaling, during liver regeneration after acute liver 
injury. HGF also stimulated HOC proliferation by increasing 
COX-2 expression. Therefore, COX-2 plays an important role in 
HOC proliferation after liver injury.
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